Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | M3554 |
| Synonyms | |
| Therapy Description |
M3554 is an antibody-drug conjugate (ADC) comprising an antibody targeting GD2 linked to the topoisomerase I inhibitor exatecan, which potentially induces cytotoxicity against GD2-positive cells and inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND08). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| M3554 | GD2 Antibody 6 | M3554 is an antibody-drug conjugate (ADC) comprising an antibody targeting GD2 linked to the topoisomerase I inhibitor exatecan, which potentially induces cytotoxicity against GD2-positive cells and inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND08). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06641908 | Phase I | M3554 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | CHE | BEL | 1 |